ClinicalTrials.gg
RecruitingNCT06185686Updated Jul 17, 2026

Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients

An observational study in Brain Tumor, Primary, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 8 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Washington University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
8 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Brain Neoplasms by Washington University School of Medicine — 5 open to participants now, 5 under way, none of them phase 3. Brain Neoplasms · Washington University School of Medicine.

Started
2024
with 1 other
Observational
2 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Brain Neoplasms by Washington University School of Medicine, this one is one of 2 that started in 2024, is one of 2 observational ones, and was the 10th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 14 studies in Brain Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 8 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease. However, this progress often comes at the cost of substantial morbidity, with cognitive deficits being the primary obstacle to independent living. Robust predictors of cognitive decline and a comprehensive understanding of the underlying mechanisms of cognitive injury remain elusive. This study will prospectively investigate alterations in brain resting state networks following radiation therapy using functional imaging. The hypothesis is that radiation therapy leads to dose-dependent alterations in functional connectivity in the networks associated with higher level cognition, ultimately leading to cognitive decline.

03

Conditions studied

  • Brain Tumor, Primary

Browse trials for

Keywords

  • Proton therapy
  • Radiation
  • Brain tumor
04

Who can participate

Ages eligible
8 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Treated at Siteman Cancer Center at Washington University School of Medicine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 8 and 21 years of age, inclusive
  • Newly diagnosed primary brain tumor of any location and any histology that will be treated with proton radiation therapy
  • of at least one year
  • Able to understand and willing to consent or assent to the research proposed (or that of a legally authorized representative, if applicable), along with consent of legal guardian(s) if applicable

Exclusion criteria

Exclusion Criteria:

  • Presence of visual impairment to an extent that the patient is unable to complete the computer testing
  • to MRI scan (i.e. due to cardiac pacemaker)
  • Presence of programmable shunt or dental braces
  • Requires sedation for MRI scans
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No

Groups and cohorts

  • Brain tumor patients receiving proton radiation therapy

    Patients between 8 and 21 years old (inclusive) with a newly diagnosed primary brain tumor that will be treated with proton radiation therapy

    Other: Cognitive testing · Device: Resting State MRI/Precision functional mapping

Interventions

  • OtherCognitive testing

    NIH Toolbox Cognitive Battery and the Novel Cognitive Measure (NCM)

  • DeviceResting State MRI/Precision functional mapping

    At baseline (before the end of radiation therapy) and approximately 12 months after the completion of radiation therapy.

    Also known as: RSFC MRI

06

What researchers measure

Primary outcomes

  1. Radiation induced effects on functional brain resting state connectivity

    The investigators will compare resting state maps of each patient pre- and post-radiation therapy. The investigators will evaluate changes in the resting state architecture and compare to the average results that would be expected from a patient in the same age and sex.

    Time frame: Through 1 year follow-up

  2. Baseline characteristics of functional network architecture

    The investigators will assess the unique architecture of brain networks at diagnosis and how significantly this architecture diverges from average healthy controls.

    Time frame: At baseline (day 1)

  3. Change in characteristics of functional network architecture

    The investigators will assess brain system segregation which is measure of the connection and disconnection between different brain networks. These will be compared within individuals and compared to healthy controls.

    Time frame: Baseline and 1 year follow-up

Secondary outcomes

  1. Correlation of radiation dose to changes in cognitive performance and resting state network connectivity

    In an exploratory fashion, the investigators will evaluate the dose of radiation received to each resting state network to determine if functional connectivity changes in a dose dependent manner at 1 year.

    Time frame: At 1 year follow-up

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine/Saint Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Recruiting
    • Stephanie Perkins, M.D. · Contactsperkins@wustl.edu · 314-747-4405
    • Stephanie Perkins, M.D. · Principal investigator
    • Scott Marek, Ph.D. · Sub investigator
    • Joshua Shimony, M.D., Ph.D. · Sub investigator
    • Margaret Shatara, M.D. · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 36 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Dec 29, 2023
StartActual
Jul 10, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06185686
Collaborators
United States Department of Defense, The Foundation for Barnes-Jewish Hospital, Children's Cancer Research Fund
Responsible party
Sponsor
First posted
Dec 29, 2023
Start date
Jul 10, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Stephanie Perkins, M.D.
Contact
sperkins@wustl.edu
314-747-4405
Stephanie Perkins, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion